- Home
- CFBK vs TARA Comparison
CFBK vs TARA Comparison
Compare CFBK & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- TARA
- Stock Information
- Founded
- CFBK 1892
- TARA N/A
- Country
- CFBK United States
- TARA United States
- Employees
- CFBK N/A
- TARA N/A
- Industry
- CFBK Major Banks
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFBK Finance
- TARA Health Care
- Exchange
- CFBK Nasdaq
- TARA Nasdaq
- Market Cap
- CFBK 141.5M
- TARA 136.3M
- IPO Year
- CFBK 1998
- TARA N/A
- Fundamental
- Price
- CFBK $21.89
- TARA $4.01
- Analyst Decision
- CFBK
- TARA Strong Buy
- Analyst Count
- CFBK 0
- TARA 4
- Target Price
- CFBK N/A
- TARA $22.67
- AVG Volume (30 Days)
- CFBK 12.5K
- TARA 223.1K
- Earning Date
- CFBK 05-06-2025
- TARA 03-05-2025
- Dividend Yield
- CFBK 1.28%
- TARA N/A
- EPS Growth
- CFBK N/A
- TARA N/A
- EPS
- CFBK 2.06
- TARA N/A
- Revenue
- CFBK $45,082,000.00
- TARA N/A
- Revenue This Year
- CFBK N/A
- TARA N/A
- Revenue Next Year
- CFBK N/A
- TARA N/A
- P/E Ratio
- CFBK $10.70
- TARA N/A
- Revenue Growth
- CFBK N/A
- TARA N/A
- 52 Week Low
- CFBK $16.92
- TARA $1.60
- 52 Week High
- CFBK $31.17
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- CFBK 39.39
- TARA 44.52
- Support Level
- CFBK $21.82
- TARA $4.41
- Resistance Level
- CFBK $22.29
- TARA $4.63
- Average True Range (ATR)
- CFBK 0.47
- TARA 0.27
- MACD
- CFBK 0.07
- TARA -0.01
- Stochastic Oscillator
- CFBK 58.49
- TARA 14.13
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).